Pathfinder 2 Study

Join the Pathfinder 2 Study with Henry Ford Health to find cancer early!

Help improve early cancer detection

Too often, cancer goes undetected until it is at an advanced stage and harder to treat. The fear and worry about the possibility of having cancer can feel debilitating.  Therefore, taking steps to find cancer early can help you feel more in control of your health. Earlier detection of cancer will also improve the chance of survival and quality of life.

A blood test designed to detect multiple types of cancer

The PATHFINDER 2 Study will test the performance of a multi-cancer early detection test, called Galleri®. The test can detect many types of cancer through a simple blood draw. 

This test is being studied and is not approved or cleared by the Food and Drug Administration (FDA). It is not meant to replace the cancer screening tests your healthcare provider may recommend, such as colonoscopy or mammography.

Who can enroll in the Study?

The PATHFINDER 2 Study is currently open to those who:

• Are 50 years or older who receive care at Henry Ford Health
• Have never been diagnosed with cancer
• Or have been cancer-free at least three years
• And are not participants in previous or ongoing GRAIL sponsored studies 

Inclusion Criteria:

1. Participants must be at least 50 years of age, inclusive, at the time of signing the Informed Consent Form (ICF).
2. Participants must be capable of giving signed and legally effective informed consent

Exclusion Criteria:

1. Undergoing or referred for diagnostic evaluation due to clinical suspicion for cancer (e.g., referred to a medical or surgical oncologist, or scheduled for biopsy on the basis of a suspicious imaging abnormality).
2. Personal history of invasive solid tumor or hematologic malignancy, diagnosed within the 3 years prior to expected enrollment date, or diagnosed greater than 3 years prior to expected enrollment date and never treated.
   
   - Individuals with a diagnosis of non-metastatic basal cell carcinoma and squamous cell carcinoma of the skin are not excluded.
   
   
3. Prior/Concurrent Concomitant Therapy (Medications/Treatments):
   
   - Definitive treatment for invasive solid tumor or hematologic malignancy within the 3 years prior to expected enrollment date. Adjuvant hormone therapy for cancer (e.g. for breast or prostate cancer) is not an exclusion criterion.
   
   
4. Individuals who will not be able to comply with the protocol procedures.
5. Individuals who are not currently registered patients at a participating center.
6. Previous or current participation in another GRAIL-sponsored study. "Participation" is defined as having signed consent and provided a blood sample.
7. Previous or current employees or contractors of GRAIL.
8. Current pregnancy (by self-report of pregnancy status)

Henry Ford Health is a national study site

Henry Ford Health will participate in this nationwide study selected by GRAIL, Inc., with the aim to improve early cancer detection.

Overseeing the study locally from our medical team:

Henry Ford Health sites that are open for participant enrollment include:

Henry Ford Cancer Institute  2800 W Grand Blvd, Detroit, MI 48202 (888) 777-4167

 

 

Henry Ford Hematology Oncology  43630 Hayes Rd, Suite 200, Clinton Township, MI 48038 (800) 436-7936

 

 

Henry Ford Medical Center - Detroit Northwest  7800 Outer Drive W, Detroit, MI 48235 (313) 543-6200

 

 

 

Henry Ford Medical Center - Ford Road  5500 Auto Club Dr, Dearborn, MI 48126 (313) 425-4500

 

 

Henry Ford Medical Center - Harbortown  3370 E Jefferson Ave, Detroit, MI 48207 (313) 656-1600

 

 

Henry Ford Medical Center - Sterling Heights  3500 15 Mile Rd, Sterling Heights, MI 48310 (586) 977-9300

 

What can a participant expect?

To participate in the PATHFINDER 2 Study, you will be asked to:

• Contact the study team to determine whether you are eligible to enroll.
• If eligible, read and sign an informed consent form that fully explains the study.
• Provide your medical history and allow Henry Ford Health team to access your medical records.
• Give a blood sample (40 mL) drawn by a trained staff at Henry Ford Health
• Complete a questionnaire around the time of receiving the Galleri test.
• Expect to receive your Galleri test result from the study team within 30 days after your blood is drawn.
• Complete 2-3 additional questionnaires during the follow-up period.

If you choose to participate in the PATHFINDER 2 Study, it is important that you continue to follow your healthcare provider’s recommendations for any cancer screening tests, such as colonoscopy or mammography. Missing recommended screening or ignoring symptoms could lead to a delayed diagnosis of cancer. 

More about the study from study sponsor GRAIL.

• Visit: https://joinpathfinder2study.com
• Early detection 
• Galleri test Galleri® | Multi-Cancer Early Detection Test
• For healthcare professionals